Translational Development Acquisition CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Translational Development Acquisition Corp. files an amendment to its 2025 annual report, revising its conclusion on disclosure controls and procedures to 'not effective'.
NASDAQ
Translational Development Acquisition Corp. files Amendment No. 1 to its 2025 Form 10-K, primarily addressing controls and procedures.
NASDAQ
Translational Development Acquisition Corp. reports its financial results for the year ended December 31, 2024, including a net loss of $71,012 and details of its initial public offering.